Triple-negative breast cancer (TNBC), the deadliest breast cancer subtype, disproportionately affects African American women – but until now, they were underrepresented in genomic studies aimed at ...

In their search for new ways to treat cancer, many scientists are using a high-tech process called genome sequencing to hunt for genetic mutations that encourage tumor cells to thrive. To aid in this ...

The image was provided by the Purdue University Collaborative Core for Cancer Bioinformatics (C3B), which brings together Purdue and Indiana University scientists to find data-driven solutions.

Esther Ugwueke is a biomedical expert and PhD student at the University of Nebraska Medical Center, United States, where she studies and researches lung cancer using bioinformatics, artificial ...

Triple-negative breast cancer (TNBC), the deadliest breast cancer subtype, disproportionately affects African American women—but until now, they have been underrepresented in genomic studies aimed at ...

Scientists at the University of Texas MD Anderson Cancer Center reported the development of a novel bioinformatics platform that predicts optimal treatment combinations for a given group of ...

The Walther Cancer Foundation will invest $11 million to advance collaborative cancer research at Indiana University and Purdue University by supporting scientists through bioinformatics — an ...

A bioinformatics analysis of pairing 64 drugs used to treat breast cancer has allowed researchers to identify 10 previously untested combinations with potential to tackle resistance to breast ...

Researchers at The University of Texas MD Anderson Cancer Center have developed a new bioinformatics platform that predicts optimal treatment combinations for a given group of patients based on co ...

A new study that sifted through an enormous mass of biomolecular data has significantly advanced our understanding of the genetics of pancreatic cancer and opened up promising treatment avenues.

Overall Count and Share for 'Bioinformatics and Computational Systems Biology of Cancer' based on the 12-month time frame mentioned above.

Computational scientists and cancer experts have devised bioinformatics software to evaluate how well current strategies distinguish cancer-promoting mutations from benign mutations in cancer cells.